Tags

Type your tag names separated by a space and hit enter

Injection sclerotherapy for oesophageal varices: a ten-year experience.
Hepatogastroenterology. 1995 Sep-Oct; 42(5):546-50.H

Abstract

BACKGROUND/AIM

Severe hemorrhage from oesophageal varices is one of the most serious complications in patients with liver cirrhosis and portal hypertension, affecting about 30-70% of the former. This paper reports the results of treatment of oesophageal varices by injection sclerotherapy.

PATIENTS AND METHODS

89 patients with oesophageal varices were treated with sclerotherapy in Oulu University Hospital in the period 1982-1991. The indication was acute bleeding in 74 cases and prophylaxis in 15.

RESULTS

Three patients died of rebleeding before eradication of the varices and nine afterwards. Rebleeding was more common in the Child B and C groups than in Child A (p < 0.01). Rebleeding did not correlate with the amount of sclerosant used. The most common complication was oesophageal stricture, noted in 15 patients, although only two required dilatation. This correlated with the amount of sclerosant used (P < 0.05). 34% of the patients died during the follow-up, the overall mortality rate being 14% in Child A cases, 35% in Child B cases and 92% in Child C cases. Mortality was 26% among the patients receiving prophylactic sclerotherapy (4/15) and 35% among those with bleeding varices 35% (26/74). Five patients were operated on for rebleeding problems, four as emergencies and one electively. Two emergency patients died.

CONCLUSION

While the number of patients in our group receiving prophylactic sclerotherapy was small, our results follow the general survival trend for bleeding varices.

Authors+Show Affiliations

Kiviniemi H
Department of Surgery, Oulu University Hospital, Finland.
Mäkelä J
No affiliation info available
Haukipuro K
No affiliation info available
Kairaluoma MI
No affiliation info available

MeSH

Acute DiseaseEsophageal and Gastric VaricesFemaleFollow-Up StudiesGastrointestinal HemorrhageHumansMaleMiddle AgedRetrospective StudiesSclerotherapySurvival RateTreatment Outcome

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8751213

Citation

Kiviniemi, H, et al. "Injection Sclerotherapy for Oesophageal Varices: a Ten-year Experience." Hepato-gastroenterology, vol. 42, no. 5, 1995, pp. 546-50.
Kiviniemi H, Mäkelä J, Haukipuro K, et al. Injection sclerotherapy for oesophageal varices: a ten-year experience. Hepatogastroenterology. 1995;42(5):546-50.
Kiviniemi, H., Mäkelä, J., Haukipuro, K., & Kairaluoma, M. I. (1995). Injection sclerotherapy for oesophageal varices: a ten-year experience. Hepato-gastroenterology, 42(5), 546-50.
Kiviniemi H, et al. Injection Sclerotherapy for Oesophageal Varices: a Ten-year Experience. Hepatogastroenterology. 1995 Sep-Oct;42(5):546-50. PubMed PMID: 8751213.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Injection sclerotherapy for oesophageal varices: a ten-year experience. AU - Kiviniemi,H, AU - Mäkelä,J, AU - Haukipuro,K, AU - Kairaluoma,M I, PY - 1995/9/1/pubmed PY - 1995/9/1/medline PY - 1995/9/1/entrez SP - 546 EP - 50 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 42 IS - 5 N2 - BACKGROUND/AIM: Severe hemorrhage from oesophageal varices is one of the most serious complications in patients with liver cirrhosis and portal hypertension, affecting about 30-70% of the former. This paper reports the results of treatment of oesophageal varices by injection sclerotherapy. PATIENTS AND METHODS: 89 patients with oesophageal varices were treated with sclerotherapy in Oulu University Hospital in the period 1982-1991. The indication was acute bleeding in 74 cases and prophylaxis in 15. RESULTS: Three patients died of rebleeding before eradication of the varices and nine afterwards. Rebleeding was more common in the Child B and C groups than in Child A (p < 0.01). Rebleeding did not correlate with the amount of sclerosant used. The most common complication was oesophageal stricture, noted in 15 patients, although only two required dilatation. This correlated with the amount of sclerosant used (P < 0.05). 34% of the patients died during the follow-up, the overall mortality rate being 14% in Child A cases, 35% in Child B cases and 92% in Child C cases. Mortality was 26% among the patients receiving prophylactic sclerotherapy (4/15) and 35% among those with bleeding varices 35% (26/74). Five patients were operated on for rebleeding problems, four as emergencies and one electively. Two emergency patients died. CONCLUSION: While the number of patients in our group receiving prophylactic sclerotherapy was small, our results follow the general survival trend for bleeding varices. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/8751213/Injection_sclerotherapy_for_oesophageal_varices:_a_ten_year_experience_ L2 - http://www.diseaseinfosearch.org/result/7025 DB - PRIME DP - Unbound Medicine ER -